Loading
Liver Disease Diagnosis and Treatment · Journal article
Acta Medica Academica · August 10, 2026
A consensus or society position rather than new primary data.
This is a national clinical practice guideline for MASLD management in Bosnia and Herzegovina, the first country-specific evidence-based recommendations for diagnosis and treatment across the disease spectrum. It emphasizes a coordinated stepwise care model through primary, secondary, and tertiary healthcare levels, with primary care serving as gatekeeper, and recommends non-invasive assessment algorithms, lifestyle modification, and selective use of GLP-1 receptor agonists and bariatric surgery.
Journal article. Adults with metabolic dysfunction–associated steatotic liver disease in Bosnia and Herzegovina.. Bosnia and Herzegovina.
MASLD is the leading cause of chronic liver disease in Bosnia and Herzegovina and a major contributor to liver- and cardiovascular-related morbidity and mortality. Primary healthcare recommended as central gatekeeper with systematic evaluation of metabolic risk factors using FIB-4 index as first-line non-invasive tool. Active case-finding of clinically significant fibrosis emphasized in high-risk populations including type 2 diabetes mellitus and obesity.
MASLD is the leading cause of chronic liver disease in Bosnia and Herzegovina and a major contributor to liver- and cardiovascular-related morbidity and mortality.
Clinicians should use these guidelines to standardize MASLD care through a coordinated primary-to-tertiary healthcare pathway, prioritize non-invasive risk assessment in primary care using FIB-4, and consider GLP-1 receptor agonists or bariatric surgery in appropriate metabolic risk subgroups.
National clinical practice guidelines providing evidence-based recommendations for diagnosis, risk stratification, and management of MASLD across the full disease spectrum in a specific healthcare system.
As stated by the source record.
Clinicians should use these guidelines to standardize MASLD care through a coordinated primary-to-tertiary healthcare pathway, prioritize non-invasive risk assessment in primary care using FIB-4, and consider GLP-1 receptor agonists or bariatric surgery in appropriate metabolic risk subgroups.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Metabolic dysfunction–associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease in Bosnia and Herzegovina and a major contributor to liver- and cardiovascular-related morbidity and mortality. These national guidelines provide the first country-specific, evidence-based recommendations for the diagnosis, risk stratification, and management of MASLD, covering the full disease spectrum from steatosis to cirrhosis and its complications. MASLD management is based on a coordinated, stepwise model across primary, secondary, and tertiary healthcare levels, with primary healthcare serving as the central gatekeeper and coordinator of care. Active case-finding of clinically significant fibrosis is emphasized, particularly in high-risk populations, such as individuals with type 2 diabetes mellitus or obesity. Primary healthcare plays a key role in early risk assessment through systematic evaluation of metabolic risk factors and first-line use of simple non-invasive tools, notably the FIB-4 index. A stepwise non-invasive diagnostic algorithm is recommended, with elastography (preferably vibration-con- trolled transient elastography or 2D shear wave elastography where available) used for further assessment in patients with in- determinate or high-risk results. Lifestyle modification and optimal management of cardiometabolic comorbidities remain the foundations of MASLD treatment. In eligible patients with type 2 diabetes mellitus and/or overweight or obesity, glucagon-like peptide-1 receptor agonists may be considered, while bariatric surgery represents an option for selected individuals with persistent obesity. Advanced MASLD, including cirrhosis, requires multidisciplinary management, surveillance for hepatocellular carcinoma, and evaluation for liver transplantation in cases of decompensation. These guidelines aim to standardize MASLD care in Bosnia and Herzegovina and strengthen the pivotal role of primary healthcare within the national MASLD care pathway.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.